Pinealon

II. What is this compound?

Pinealon (Glu-Asp-Arg, or EDR) weighs approximately 418 daltons — small enough, in principle, to reach places larger peptides can't. It belongs to the class of peptide bioregulators: short amino acid chains proposed to interact directly with cellular DNA and influence gene expression. The tripeptide consists of L-glutamic acid, L-aspartic acid, and L-arginine, and emerged from the broader program of synthetic bioregulatory peptides at the St. Petersburg Institute of Bioregulation and Gerontology [2] PMID: 21978084 .

The bioregulator concept is what separates pinealon from conventional receptor-targeting peptides. Khavinson's group hypothesized that very short peptides — just 2 to 4 amino acids — can enter the cell nucleus and influence transcription by binding to promoter regions of specific genes. That places pinealon in the same scientific family as epitalon Epitalon tetrapeptide Pineal peptide studied for telomerase activation and longevity (Ala-Glu-Asp-Gly) and vesugen, though each targets different tissues and gene sets.

In research settings, pinealon has been administered via intraperitoneal injection in animal models. Its extremely small size suggests favorable bioavailability and potential for CNS penetration, though formal pharmacokinetic characterization in humans has not been conducted — one reason the mechanism section below leans heavily on the proposed rather than the proven. All available data derive from preclinical studies and small-scale clinical observations in Russian populations.

III. How it works

Pinealon's proposed mechanism reads almost heretical next to mainstream peptide research: direct gene expression modulation. Where conventional peptides bind surface receptors and trigger signaling cascades, pinealon is hypothesized to penetrate the cell nucleus and interact with DNA promoter regions, influencing transcription of genes involved in cellular survival and maintenance [3] PMID: 33396470 .

The best-documented effect is ROS suppression. In cell culture studies, pinealon restricted reactive oxygen species accumulation in a dose-dependent manner: when neurons faced oxidative stress conditions, pinealon-treated cells showed significantly lower ROS levels and reduced necrosis rates compared to untreated controls. Notably, this antioxidant effect arrived at concentrations substantially lower than compounds like carnosine require for comparable protection [4] PMID: 21978084 .

A second pathway runs through apoptosis regulation. Research indicates pinealon modulates expression of caspase-3 — a key executioner enzyme in programmed cell death — and the tumor suppressor protein p53. By downregulating caspase-3 activity, pinealon may reduce the rate of neuronal apoptosis under stress conditions, while the p53 modulation hints at a more complex role in cell-cycle regulation than simple antioxidant protection alone [5] PMID: 33396470 .

Third, evidence points to mitochondrial function support: studies examining cytochrome C oxidase, a critical enzyme in the mitochondrial electron transport chain, suggest pinealon may influence mitochondrial respiratory capacity — connecting it to the broader category of mitochondrial-targeted research compounds [6] PMID: 21978084 . Elegant mechanisms only matter once they show up in living models, though — which is where the benefits data picks up.

• Suppression of reactive oxygen species (ROS) accumulation in neurons
  PMID 21978084
• Gene expression modulation via direct DNA interaction in brain and pineal tissue
  PMID 33396470
• Regulation of caspase-3 and p53 to reduce neuronal apoptosis
  PMID 33396470
• Modulation of cytochrome C oxidase activity in mitochondria
  PMID 21978084

IV. Research Findings

The strongest preclinical finding is neuroprotection under oxidative stress. In rat models of prenatal hyperhomocysteinemia — a condition that damages developing neurons through NMDA receptor overactivation and ROS accumulation — pinealon administration to pregnant dams protected offspring from cognitive deficits. Treated offspring showed improved spatial learning in Morris water maze tests and enhanced neuronal resistance to hydrogen peroxide-induced oxidative stress [7] PMID: 21978084 . For a brain-development model, protection reaching the next generation is a striking result.

Cognitive function preservation appeared elsewhere too: pinealon maintained learning retention in rats with experimentally induced diabetes, a condition known to impair hippocampal function through oxidative and inflammatory pathways — consistent with the compound's proposed gene-expression mechanism in brain tissue [8] PMID: 21978084 .

Geroprotective signals form the third axis — and the closest thing to human data. A clinical observation study in elderly patients with organic brain syndrome reported that pinealon combined with vesugen improved markers of biological aging and CNS function, suggesting anabolic and neuroprotective properties that may slow the rate of biological aging. The non-randomized design and small sample size cap how much weight those conclusions can carry [9] PMID: 26390612 .

Finally, cellular resilience extends beyond the nervous system: in vitro studies on skin fibroblasts from elderly donors found pinealon improved cell viability and proliferative capacity, hinting at tissue-protective effects that reach past the brain [10] PMID: 22803085 .

• neuroprotection preclinical
  PMID 21978084PMID 33396470
• cognitive-function preclinical
  PMID 21978084
• anti-aging preclinical
  PMID 26390612
• cellular-resilience preclinical
  PMID 21978084PMID 22803085

V. Dosage Context Explained

Published dosing data for pinealon are sparse, and what exists is strictly rodent-scale. The most cited preclinical study employed 10 μg/kg/day administered intraperitoneally for 5 consecutive days in a rat model of prenatal hyperhomocysteinemia — a dose chosen to probe neuroprotective effects during a specific developmental window [11] PMID: 21978084 .

In the clinical observation study involving elderly patients, pinealon was administered alongside vesugen, though specific dosing parameters weren't consistently reported in the English-language abstract [12] PMID: 26390612 . The Russian clinical literature references pinealon as a "cytogen" preparation — tissue-specific peptide bioregulators typically administered in short courses. Intranasal delivery has been discussed for CNS-targeted research, leveraging the tripeptide's small size for potential olfactory-route brain penetration, but standardized intranasal protocols haven't appeared in peer-reviewed literature.

Treat every figure here as a research-context reference point. No regulatory agency has established approved dosing guidelines for human use, and translating rat intraperitoneal doses across species or routes is unreliable — which is precisely why the safety record, thin as it is, matters next.

• Administration Routes

  intraperitoneal

  Range

  10 μg/kg/day for 5 days

  rat model of prenatal hyperhomocysteinemia

  PMID 21978084

VI. Side Effects: Research Context

Pinealon's published safety record is striking mainly for how little is in it. Available preclinical studies report no adverse effects at the doses tested, suggesting a favorable margin in animal models — but that silence reflects the narrow scope of the research rather than comprehensive toxicological evaluation. No formal toxicology programs, dose-escalation safety trials, or long-term carcinogenicity assessments have been published.

The compound's proposed direct-DNA mechanism raises theoretical questions about off-target gene modulation, though no evidence of genotoxicity has been reported. One theoretical contraindication follows logically from the biology: active malignancy. Any compound that modulates gene expression and cell survival pathways warrants caution in oncological contexts — particularly given the observed p53 modulation, since p53 sits at the center of tumor suppression [13] PMID: 33396470 .

With no systematic human pharmacovigilance data available, extrapolating risk from preclinical findings to people remains speculative — an uncertainty worth holding alongside the regulatory picture below.

• none documented in preclinical models

VII. Frequently Asked Questions